Biologics and Vaccines for Nasal and Pulmonary Drug Delivery

Komalla, V; Haghi, M; Kayser, V

Biologics and Vaccines for Nasal and Pulmonary Drug Delivery

Komalla, V Haghi, M

Kayser, V

Permalink

Publisher:: Springer Nature
Publication Type:: Chapter
Citation:: Advanced Drug Delivery Strategies for Targeting Chronic Inflammatory Lung Diseases, 2022, pp. 493-521
Issue Date:: 2022-03-24

Closed Access

	Filename	Description	Size
	978-981-16-4392-7_21.pdf	Published version	439.15 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Komalla, V
dc.contributor.author	Haghi, M https://orcid.org/0000-0002-3362-1845
dc.contributor.author	Kayser, V
dc.date.accessioned	2023-04-11T23:54:57Z
dc.date.available	2023-04-11T23:54:57Z
dc.date.issued	2022-03-24
dc.identifier.citation	Advanced Drug Delivery Strategies for Targeting Chronic Inflammatory Lung Diseases, 2022, pp. 493-521
dc.identifier.isbn	978-981-16-4391-0
dc.identifier.uri	http://hdl.handle.net/10453/169616
dc.description.abstract	Biologics are a rapidly emerging class of therapeutics that have succeeded clinically and commercially due to their specificity and efficacy against various diseases including cancer, inflammatory, and autoimmune diseases. Even though most biologics are administered parenterally, nasal and pulmonary delivery would be beneficial due to numerous advantages such as being patient-friendly, noninvasive, cost-effective, and less toxic. While there are currently a few nasal and inhaled biologics on the market, for example, Suprefact®, Minirin®, Miacalcin®, most of them are designed to treat ailments related to prostate carcinoma, diabetes, osteoporosis but not for respiratory diseases. Moreover, there are some marketed nasally delivered vaccines such as Flumist® and Nasovac-S® against influenza virus, inhaled vaccines that did not make it to market. Given the rise of respiratory infections such as MERS, SARS, and SARS-CoV-2, a great deal of interest exists in developing nasal and pulmonary-delivered biologics and vaccines for respiratory diseases. The objective of this chapter is to describe the potential for pulmonary and nasal delivery of biologics. Each section delves into introducing biologics and vaccines, followed by a portrayal of recent updates on nasal and pulmonary delivery of biologics and vaccines. The most promising formulation strategies for enhancing the stability and therapeutic efficacy of biologics as a part of research and development will be discussed.
dc.format.extent	27
dc.language	en
dc.publisher	Springer Nature
dc.relation.ispartof	Advanced Drug Delivery Strategies for Targeting Chronic Inflammatory Lung Diseases
dc.relation.isbasedon	10.1007/978-981-16-4392-7_21
dc.rights	info:eu-repo/semantics/closedAccess
dc.title	Biologics and Vaccines for Nasal and Pulmonary Drug Delivery
dc.type	Chapter
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
utslib.copyright.status	closed_access	*
pubs.consider-herdc	false
dc.date.updated	2023-04-11T23:54:56Z
pubs.place-of-publication	Singapore
pubs.publication-status	Published
dc.location	Singapore

Abstract:

Biologics are a rapidly emerging class of therapeutics that have succeeded clinically and commercially due to their specificity and efficacy against various diseases including cancer, inflammatory, and autoimmune diseases. Even though most biologics are administered parenterally, nasal and pulmonary delivery would be beneficial due to numerous advantages such as being patient-friendly, noninvasive, cost-effective, and less toxic. While there are currently a few nasal and inhaled biologics on the market, for example, Suprefact®, Minirin®, Miacalcin®, most of them are designed to treat ailments related to prostate carcinoma, diabetes, osteoporosis but not for respiratory diseases. Moreover, there are some marketed nasally delivered vaccines such as Flumist® and Nasovac-S® against influenza virus, inhaled vaccines that did not make it to market. Given the rise of respiratory infections such as MERS, SARS, and SARS-CoV-2, a great deal of interest exists in developing nasal and pulmonary-delivered biologics and vaccines for respiratory diseases. The objective of this chapter is to describe the potential for pulmonary and nasal delivery of biologics. Each section delves into introducing biologics and vaccines, followed by a portrayal of recent updates on nasal and pulmonary delivery of biologics and vaccines. The most promising formulation strategies for enhancing the stability and therapeutic efficacy of biologics as a part of research and development will be discussed.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/169616